Endothelin receptors in normal and diseased kidneys

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 4, 1996, Pages 326-330

  Nambi, Ponnal ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

antagonists; antibodies; cyclosporine; endothelin; kidney; radiocontrast; re ceptor; renal failure

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; CP 170687; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; INDOMETACIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; CONFERENCE PAPER; DOG; HUMAN; HUMAN TISSUE; KIDNEY; MONKEY; NEPHROTOXICITY; NONHUMAN; RABBIT; RAT; SWINE;

EID: 0030010672     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02832.x     Document Type: Conference Paper

References (86)

1. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
2. Sokolovsky M. Endothelins and sarafotoxins: Physiological regulation, receptor subtypes and transmembrane signalling. Pharmacol. Ther. 1992; 54: 129-49.
3. Thomas CP, Simonson MS, Dunn MJ. Endothelin: Receptor and transmembrane signals. NIPS 1993; 207.
4. Huggins JP, Pelton JT, Miller RC. The structure and specificity of endothelin receptors: Their importance in physiology and medicine. Pharmacol. Ther. 1993; 59: 55-123.
5. Watanabe H, Miyazaki H, Kondoh M et al. Two distinct types of endothelin receptors are present on chick cardiac membranes. Biochem. Biophys. Res. Commun. 1989; 161: 1252-9.
6. Masuda Y, Miyazaki H, Kondoh M et al. Two different forms of endothelin receptors in rat lung. FEBS Lett. 1989; 257: 208-10.
7. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2.
8. Sakurai T, Yanagisawa M, Takuma Y et al. Cloning of a cDNA encoding a nonisopeptide-selective subtype of an endothelin receptor. Nature 1990; 348: 732-5.
9. Lin HY, Kaji EH, Winkel GK, Ives HE, Lodish HF. Cloning and functional expression of a vascular smooth muscle endothelin-1 receptor. Proc. Natl Acad. Sci. USA 1991; 88: 3185-98.
10. Elshourbagy NA, Lee JA, Korman DR et al. Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum. Mol. Pharmacol. 1992; 41: 465-73.
11. Elshourbagy NA, Korman DR, Wu H-L et al. Molecular characterization and regulation of the human endothelin receptors. J. Biol. Chem. 1993; 268: 3873-9.
12. Nakamuta M, Takayanagi R, Sakai Y et al. Cloning and sequence analysis of a cDNA encoding human non-selective type of endothelin receptor. Biochem. Biophys. Res. Commun. 1991; 177: 34-9.
13. Ogawa Y, Nakao K, Arai H et al. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem. Biophys. Res. Commun. 1991; 178: 248-55.
14. B endothelin receptor. Biochem. Biophys. Res. Commun. 1991; 178: 656-63.
15. Kumar C, Mwangi V, Nuthulaganti P et al. Cloning and characterization of a novel endothelin receptor from Xenopus heart. J. Biol. Chem. 1994; 269: 13414-20.
16. C receptor) from Xenopus laevis dermal melanophores. J. Biol. Chem. 1993; 268: 19 126-33.
17. Jones CR, Hiley CR, Pelton JT, Miller RC. Autoradiographic localisation of ET binding sites in kidney. Eur. J. Pharmacol. 1989; 163: 379-82.
18. Kohzuki M, Johnston CI, Chai SY, Casley DJ, Mendelsohn FAO. Localization of ET receptors in rat kidney. Eur. J. Pharmacol. 1989; 160: 193-4.
19. Gauquelin G, Thibault G, Garcia R. Characterization of renal glomerular ET receptors in the rat. Biochem. Biophys. Res. Commun. 1989; 164: 54-7.
20. Martin ER, Brenner BM, Ballermann BJ. Heterogeneity of cell surface ET receptors. J. Biol. Chem. 1990; 265: 14044-9.
21. Kohzuki M, Johnston CI, Abe K et al. In vitro autoradiographic ET-1 binding sites and sarafotoxin S6B binding sites in rat tissues. Clin. Exp. Pharmacol. Physiol. 1991; 18: 509-15.
22. Nambi P, Wu H-L, Pullen M, Aiyar N, Bryan H, Elliott J. Identification of ET receptor subtypes in rat kidney cortex using subtype-selective ligands. Mol Pharmacol. 1992; 42: 336-9.
23. Nambi P, Pullen M, Wu H-L, Aiyar N, Ohlstein EH, Edwards RM. Identification of ET receptor subtypes in human renal cortex and medulla using subtype-selective ligands. Endocrinology 1992; 131: 1081-6.
24. Kohan DE, Hughes AK, Perkins SL. Characterization of ET receptors in the inner medullary collecting duct of the rat. J. Biol. Chem. 1992; 267: 12336-40.
25. B in human kidney. Kidney Int. 1993; 44: 36-42.
26. Takemoto F, Uchida S, Ogata E, Kurokawa K. Endothelin-1 and ET-3 binding to rat nephrons. Am. J. Physiol. 1993; 264: F827-32.
27. B receptors increases glomerular cGMP via an L-arginine-dependent pathway. Am. J. Physiol. 1992; 263: F1020-5.
28. Takeda M, Breyer MD, Noland TD et al. Endothelin-1 receptor antagonist: Effects on ET- and cyclosporine-treated mesangial cells. Kidney Int. 1992; 42: 1713-19.
29. Albrightson CR, Pullen M, Wu H-L, Dytko G, Hersh LB, Nambi P. Thrombin-mediated down regulation of endothelin receptors in mesangial cells coincides with the down regulation of neutral endopeptidase activity. Mol. Pharmacol. 1995; 47: 1156-63.
30. Sugiura M, Snadjar RM, Schwartzberg M, Badr KF, Inagami T. Identification of two types of specific ET receptors in rat mesangial cell. Biochem. Biophys. Res. Commun. 1989; 162: 1396-401.
31. Hori S, Komatsu Y, Shigemoto R, Mizuno N, Nakanishi S. Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology 1992; 130: 1885-95.
32. Kon V, Badr KF. Biological actions and pathophysiologic significance of ET in the kidney. Kidney Int. 1991; 40: 1-12.
33. Brooks DP, DePalma PD, Gellai M et al. Non-peptide ET receptor antagonists III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs, J. Pharmacol. Exp. Ther. 1994; 271: 769-75.
34. Marsen TA, Schramek H, Dunn MJ. Renal actions of ET: Linking cellular signaling pathways to kidney disease. Kidney Int. 1994; 45: 336-44.
35. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma ET immunoreactivity in liver disease and the hepatorenal syndrome. N. Engl. J. Med. 1992; 327: 1774-8.
36. Ohta K, Hirata Y, Shichiri M, Ichioka M, Kubota T, Marumo F. Cisplatin-induced urinary ET excretion. J A M A 1991; 265: 1391-2.
37. Heyman SN, Clark BA, Kaiser N et al. In vivo and in vitro studies on the effect of amphotericin B on ET release. J. Antimicrob. Chemother. 1992; 29: 69-77.
38. Kelleher JP, Shah V, Godley ML et al. Urinary ET (ET1) in complete ureteric obstruction in the miniature pig. Urol. Res. 1992; 20; 63-5.
39. Morise Z, Ueda M, Aiura K, Endo M, Kitajima M. Pathophysiologic role of ET-1 in renal function in rats with endotoxin shock. Surgery 1994; 115: 199-204.
40. Firth JD, Ratcliffe PJ. Organ distribution of the three rat ET messenger RNAs and the effects of ischaemia on renal gene expression. J. Clin. Invest. 1992; 90: 1023-31.
41. Tomita K, Ujiie K, Nakanishi T et al. Plasma ET levels in patients with acute renal failure. N. Engl. J. Med. 1989; 321: 1127.
42. Clozel M, Löffler BM, Gloor H. Relative preservation of the responsiveness to ET-1 during reperfusion following renal ischaemia in the rat. J. Cardiovasc. Pharmacol. 17 (Suppl. 7): S313-15.
43. Nambi P, Pullen M, Jugus M, Gellai M. Rat kidney ET receptors in ischaemia-induced acute renal failure. J. Pharmacol. Exp. Ther. 1993; 264: 345-8.
44. Wilkes BM, Pearl AR, Mento PF, Maita ME, Macica CM, Girardi EP. Glomerular ET receptors during initiation and maintenance of ischemic acute renal failure in rats. Am. J. Physiol. 1991; 260: F110-18.
45. Roubert P, Gillard-Roubert V, Pourmarin L et al. Endothelin receptor subtypes A and B are up-regulated in an experimental model of acute renal failure. Mol. Pharmacol. 1993; 45: 182-8.
46. López-Farré A, Gómez-Garre D, Bernabeu F, López-Novoa J. A role for ET in the maintenance of post-ischaemic renal failure in the rat. J. Physiol. 1991; 444: 513-22.
47. Shibouta Y, Suzuki N, Shino A et al. Pathophysiological role of endothelin in acute renal failure. Life Sci. 1990; 46: 1611-18.
48. Mino N, Kobayashi M, Nakajima A et al. Protective effect of a selective ET receptor antagonist, BQ123, in ischemic acute renal failure in rats. Eur. J. Pharmacol. 1992; 221: 77-83.
49. Chan L, Chittinandana A, Shapiro JI, Shanley PF, Schrier RW. Effect of an ET-receptor antagonist on ischemic acute renal failure. Am. J. Physiol. 1994; 266: F135-8.
50. A receptor antagonist in the rat. J. Clin. Invest. 1994; 93: 900-6.
51. Gellai M, Jugus M, Fletcher TA et al. The ET receptor antagonist, (+)-SB 209670, reverses ischaemia-induced acute renal failure (ARF) in the rat. FASEB J. 1994; 8: A260.
52. Clozel M, Breu V, Burri K et al. Pathophysiological role of ET revealed by the first orally active ET receptor antagonist. Nature 1993; 365: 759-61.
53. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Biological role for the ET-A receptor in aortic cross-clamping. Hypertension 1993; 22: 62-6.
54. Brooks DP, Contino LC, Storer B, Ohlstein EH. Increased ET excretion in rats with renal failure induced by partial nephrectomy. Br. J. Pharmacol. 1991; 104: 987-9.
55. Benigni A, Perico N, Gaspari F et al. Increased renal ET production in rats with reduced renal mass. Am. J. Physiol. 1991; 260: F331-9.
56. Orisio S, Benigni A, Bruzzi I et al. Renal ET gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 1993; 43: 354-8.
57. Fukui M, Nakamura T, Ebihara I et al. Gene expression for ETs and their receptors in glomeruli of diabetic rats. J. Lab. Clin. Med. 1993; 122: 149-55.
58. Nakamura T, Ebihara I, Fukui M et al. Increased ET and ET receptor mRNA expression in polycystic kidneys of cpk mice. J. Am. Soc. Nephrol. 1993; 4: 1064-72.
59. Koyama H, Nishizawa Y, Morii EH, Tabata T, Inoue T, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989; i: 991-2.
60. Predel HG, Meyer-Lehnert, Backer A, Stelkens H, Kramer HJ. Plasma concentrations of endothelin in patients with abnormal vascular reactivity. Effects of ergometric exercise and acute saline loading. Life Sci. 1990; 47: 1837-43.
61. Warrens AN, Cassidy MJ, Takahashi K, Ghatei MA, Bloom SR. Endothelin in renal failure. Nephrol. Dial. Transplant. 1990; 5: 418-22.
62. Stockenhuber F, Gottsauner-Wolf M, Marosi L, Liebisch B, Kurz RW, Balcke P. Plasma levels of ET in chronic renal failure and after renal transplantation: Impact on hypertension and cyclosporin A-associated nephrotoxicity. Clin. Sci. 1992; 82: 255-8.
63. Collier A, Leach JP, McLellan A, Jardine A, Morton JJ, Small M. Plasma ET-like immunoreactivity levels in IDDM patients with microalbuminuria. Diab. Care 1992; 15: 1038-40.
64. Lee Y-J, Shin S-J, Tsai J-H. Increased urinary ET-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diab. Care 1994; 17: 263-6.
65. Saito Y, Kazuwa N, Shirakami G et al. Endothelin in patients with chronic renal failure. J. Cardiovasc. Pharmacol. 1991; 17 (Suppl. 7): S437-9.
66. Benigni A, Zoja C, Corna D et al. A specific ET subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993; 44: 440-4.
67. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of ET by cultured human endothelial cells. J. Clin. Invest. 1991; 88: 310-14.
68. Nakahama H. Stimulatory effect of cyclosporine A on ET secretion by a cultured renal epithelial cell line, LLC-PK1 cells. Eur. J. Pharmacol. 1990; 180: 191-2.
69. Moutabarrik A, Ishibashi M, Fukunaga M et al. FK506 mechanism of nephrotoxicity: Stimulatory effect on ET secretion by cultured kidney cells. Transplant. Proc. 1991; 23: 3133-6.
70. Brooks DP, Ohlstein EH, Contino LC et al. Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary ET excretion and renal ET receptor number. Eur. J. Pharmacol. 1994; 194: 115-17.
71. Benigni A, Perico N, Ladny JR, Imberti O, Bellizzi L, Remuzzi G. Increased urinary excretion of ET-1 and its precursor, big-ET-1, in rats chronically treated with cyclosporine. Transplantation 1991; 52: 175-7.
72. Edwards BS, Hunt SA, Fowler MB, Valentine HA, Anderson LM, Lerman A. Effect of cyclosporine on plasma ET levels in humans after cardiac transplantation. Am. J. Cardiol. 1991; 67: 782-4.
73. Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Cyclosporine-induced elevation in circulating ET-1 in patients with solid-organ transplants. Transplantation 1993; 56: 880-4.
74. Nambi P, Pullen M, Contino LC, Brooks DP. Upregulation of renal ET receptors in rats with cyclosporine A-induced nephrotoxicity. Eur. J. Pharmacol. 1990; 187: 113-16.
75. Nayler WG, Gu XH, Casley DJ, Panagiotopoulos S, Liu J, Mottram PL. Cyclosporine increases ET-1 binding site density in cardiac cell membranes. Biochem. Biophys. Res. Commun. 1989; 163: 1270-4.
76. Awazu M, Sugiura M, Inagami T, Ichikawa I, Kon V. Cyclosporine promotes glomerular ET binding in vivo. J. Am. Soc. Nephrol. 1991; 1: 1253-8.
77. B receptors in response to cyclosporine in mesangial cells. Am. J. Pathol. 1994; 144: 473-9.
78. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. Role of ET in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990; 37: 1487-91.
79. Bloom ITM, Bentley FR, Garrison RN. Acute cyclosporine-induced renal vasoconstriction is mediated by ET-1. Surgery 1993; 114: 480-8.
80. Fogo A, Hellings SE, Inagami T, Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 1992; 42: 770-4.
81. Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J. Am. Soc. Nephrol. 1990; 1: 76-83.
82. Margulies KB, Hildebrand FL, Heublein DM, Burnett JC Jr. Radiocontrast increases plasma and urinary ET. J. Am. Soc. Nephrol. 1991; 2: 1041-5.
83. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M, Epstein FH. Radiocontrast agents induce ET release in vivo and in vitro. J. Am. Soc. Nephrol. 1992; 3: 58-65.
84. Brooks DP, DePalma PD. Blockade of radiocontrast-induced renal vasoconstriction by the ET receptor antagonist, SB 209670. J. Am. Soc. Nephrol. 1994; 5: 918.
85. Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH. Role of ET and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int. 1993; 44: 1217-23.
86. Gellai M, DeWolf R, Pullen M, Nambi P. Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int. 1994; 46: 1287-94.